Skip to main content
. 2017 Oct 17;17:691. doi: 10.1186/s12885-017-3679-5

Table 5.

Results of cost-effectiveness analysis (BRL/ months of life gained)

Strategy Cost (R$) Incremental cost (R$) Effectiveness (MLG) Incremental effectiveness (MLG) ICER
(BRL/MLG)
XELOX 41,396.84 97.07
XELOX + bevacizumab 89,230.41 47,833.57 99.32 2.25 21,231.43

Abbreviations: ICER Incremental cost-effectiveness ratio, MLG months of life gained, XELOX Xeloda® and oxaliplatin; BRL Brazilian real